Corcept Therapeutics Incorporated (CORT)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.24 | 1.23 | 1.20 | 1.20 | 1.23 | 1.29 | 1.24 | 1.17 | 1.16 | 1.13 | 1.12 | 1.15 | 1.13 | 1.08 | 1.09 | 1.08 | 1.09 | 1.09 | 1.10 | 1.09 |
Corcept Therapeutics Incorporated's solvency ratios indicate a consistently low level of indebtedness over the years. The Debt-to-assets ratio, Debt-to-capital ratio, and Debt-to-equity ratio have all been reported as 0.00, suggesting that the company has minimal debt relative to its total assets, capital, and equity.
The Financial leverage ratio, which measures the company's financial leverage or the proportion of debt in its capital structure, has shown a slight increase from 1.09 in March 2020 to around 1.24 by June 2023, before stabilizing around 1.20 in the most recent period. This indicates that the company has a moderate level of financial leverage, but it has remained relatively stable and not a cause for concern.
Overall, based on the solvency ratios provided, Corcept Therapeutics Incorporated appears to be in a strong financial position with low levels of debt and a manageable level of financial leverage, which suggests a healthy ability to meet its financial obligations in the long term.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | — | 39.82 | 35.61 | 33.77 | 14.74 | 17.99 | 15.14 | 14.17 | 31.67 | 68.47 | 153.51 | 394.04 | 235.31 | 156.93 | 81.91 | 49.97 | 37.71 | 29.19 | 26.74 | 23.96 |
The interest coverage ratio measures the ability of Corcept Therapeutics Incorporated to meet its interest obligations based on its earnings. A higher interest coverage ratio indicates that the company is more capable of servicing its debt.
Analyzing the trend in Corcept Therapeutics Incorporated's interest coverage ratio from March 2020 to December 2024, we observe a significant improvement over time. The ratio has shown a consistent upward trajectory, starting at 23.96 in March 2020 and reaching a peak of 394.04 in March 2022. This substantial increase reflects the company's enhanced ability to cover its interest expenses with its earnings.
However, from June 2022 onwards, the interest coverage ratio begins to decline, dropping to 14.17 in March 2023 and fluctuating around this level over the subsequent quarters. This downward trend may indicate a potential decrease in earnings or an increase in interest expenses relative to income during this period.
Overall, the interest coverage ratio for Corcept Therapeutics demonstrates a strong performance in the earlier years, with a notable peak in March 2022, but the subsequent fluctuation and decline in the ratio from June 2022 onwards suggest a need for continued monitoring of the company's ability to meet its interest obligations in the coming periods.